Nanoscope Therapeutics has received priority review from PMDA for MOGENRY®, a groundbreaking optogenetic therapy aimed at treating inherited retinal dystrophies in Japan.

At the upcoming Cell & Gene Meeting on the Mesa 2026, Nanoscope Therapeutics will unveil advancements in optogenetic therapies, particularly MOGENRY for retinal degeneration.

Nanoscope Therapeutics has partnered with InspiroGene by McKesson to distribute its innovative retinal therapy, enhancing patient care in the US.

Editor’s note: This is a developing news story. Please check back soon for updates. The FDA accepted a biologics license application for Mogenry, Nanoscope Therapeutics’ investigational therapy designed for vision restoration in retinitis pigmentosa, according to a press release. Mogenry (sonpiretigene isteparvovec), also known as MCO-010, is a one-time intravitreal optogenetic gene therapy. If the therapy is approved, the company said it would be the first gene-agnostic therapy to improve vision in patients with severe vision loss from retinitis pigmentosa. The submission was supported by the

Nanoscope Therapeutics will present pivotal trial data on its optogenetic therapy at the Euretina Congress 2026, marking a milestone in vision restoration.

Join Nanoscope Therapeutics at the prestigious 28th Annual H.C. Wainwright Global Investment Conference to witness cutting-edge breakthroughs in biotechnology.

Editor’s note: This is a developing news story. Please check back soon for updates. The FDA accepted a biologics license application for Mogenry, Nanoscope Therapeutics’ investigational therapy designed for vision restoration in retinitis pigmentosa, according to a press release. Mogenry (sonpiretigene isteparvovec), also known as MCO-010, is a one-time intravitreal optogenetic gene therapy. If the therapy is approved, the company said it would be the first gene-agnostic therapy to improve vision in patients with severe vision loss from retinitis pigmentosa. The submission was supported by the

Nanoscope Therapeutics announces the FDA's acceptance of its Biologics License Application for MOGENRY, a gene therapy aimed at restoring vision for those suffering from severe retinitis pigmentosa.

Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed M...

Nanoscope Therapeutics Inc. has named Paul Hallen as chief operating officer as it advances commercialization of its MOGENRY gene therapy.

Nanoscope Therapeutics announced the appointment of Paul Hallen as their new COO to enhance operational efficiency and commercial readiness for MOGENRY.